Skip to main content
IlluminaLaunch

Illumina releases SpliceAI2 to help advance rare disease research

Source: Autobound Signal API · 103 signals tracked for Illumina · updated

Get Illumina's live signals in Claude or ChatGPT, or by API

AskWhat changed at Illumina this week? Use Autobound signals for illumina.com.

What happened

Illumina introduced SpliceAI2, a genomic AI model designed to predict splice variants and assess the functional consequences of genetic variation in rare disease research.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impact SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 helps researchers identify disease-relevant splice variants that otherwise may go unnoticed. Predicting splice effects is key to resolving variants of uncertain significance in rare disease research, hereditary cancer testing research, and drug discovery. When applied to a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models. "Variant effect prediction tools, such as SpliceAI2, are among the key areas of focus for the BioInsight AI Lab," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. "As researchers work to elucidate the effect of mutations, we are uniquely positioned to unite genomic data and scientific expertise at scale, delivering the AI tools that can advance discovery and human health." The BioInsight AI Lab focuses on three main areas of scientific impact...

Keep reading with a free account

The rest of this article, and every signal for Illumina, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Launch

What this signalsA launch often needs new go-to-market and support spend.

Product
SpliceAI2
Takes effect
Oct 8, 2026
Location
San Diego, California, United States

More launch signals at other companies

The full record

From the Signal API record

Details

Release type
Model

Topics and mentions

Product tags

  • online technology
  • general technology
  • future tech
  • medical
  • data

Extraction

Confidence
95%
Detected
Oct 8, 2026
signal_type
news
signal_subtype
launches

Use this data

Get every launch signal for Illumina and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Illumina this week?”

  2. Send it to your own tools

    The Signal API returns launch signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/4bf71529-4776-072b-96a3-4fcae7b77688 returns this record as JSON. POST /v1/companies/enrich returns every signal for illumina.com.

{
  "signal_id": "4bf71529-4776-072b-96a3-4fcae7b77688",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-10-08T13:15:00+00:00",
  "company": {
    "name": "Illumina",
    "domain": "illumina.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/illumina-releases-spliceai2-to-help-advance-rare-disease-research-302902489.html",
    "title": "Illumina releases SpliceAI2 to help advance rare disease research",
    "excerpt": "In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impact SAN DIEGO , Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 helps researchers identify disease-relevant splice variants that otherwise may go unnoticed. Predicting splice effects is key to resolving variants of uncertain significance in rare disease research, hereditary cancer testing research, and drug discovery. When applied to a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models. \"Variant effect prediction tools, such as SpliceAI2, are among the key areas of focus for the BioInsight AI Lab,\" said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. \"As researchers work to elucidate the effect of mutations, we are uniquely positioned to unite genomic data and scientific expertise at scale, delivering the AI tools that can advance discovery and human health.\" The BioInsight AI Lab focuses on three main areas of scientific impact...",
    "product": "SpliceAI2",
    "summary": "Illumina introduced SpliceAI2, a genomic AI model designed to predict splice variants and assess the functional consequences of genetic variation in rare disease research.",
    "location": "San Diego, California, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS2004802/Illumina-Inc-Photo.jpg?id=OA2993901&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "SpliceAI2",
      "full_text": "SpliceAI2, a new genomic AI model",
      "fuzzy_match": false,
      "release_type": "model"
    },
    "product_tags": [
      "online_technology",
      "general_technology",
      "future_tech",
      "medical",
      "data"
    ],
    "published_at": "2026-10-08T13:15:00Z",
    "location_data": [
      {
        "city": "San Diego",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-08",
    "article_sentence": "Illumina, Inc. (NASDAQ: ILMN ) today introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.